{'fraction_non_alphanumeric': 0.027280477408354646, 'fraction_numerical': 0.015345268542199489, 'mean_word_length': 5.8654970760233915, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hemagglutinin‐based DNA vaccines containing trimeric self‐assembling nanoparticles confer protection against influenza

Influenza viruses continue to threaten public health, and currently available vaccines provide insufficient immunity against seasonal and pandemic influenza. The use of recombinant trimeric hemagglutinin (HA) as an Ag provides an attractive alternative to current influenza vaccines. Aiming to develop an effective vaccine with rapid production, robust immunogenicity, and high protective efficiency, a DNA vaccine was designed by fusing influenza virus HA with self‐assembled ferritin nanoparticles, denoted as HA‐F. This candidate vaccine was prepared and purified in a 293–6E cell eukaryotic expression system. After BALB/c mice were immunized with 100 μg of HA‐F DNA 3 times, HA‐F elicited significant HA‐specific humoral immunity and T cell immune responses. The HA‐F DNA vaccine also conferred protection in mice against a lethal infection of homologous A/17/California/2009/38 (H1N1) virus. These results suggest that the HA‐F DNA vaccine is a competitive vaccine candidate and presents a promising vaccination approach against influenza viruses.